[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605575":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":67,"collaborators":49,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":49,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":49,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":49,"overallStatus":54,"whyStopped":49,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Ioannina","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","EXPERIMENTAL","Group 1 will receive a tranexamic acid dosage of 10mg\u002Fkg prior to operation start, followed by transfusion rate of 1mg\u002Fkg\u002Fh until the end of the surgery.",[13],"Drug: Tranexamic acid at a dose of 10 mg\u002Fkg followed by 1 mg\u002Fkg\u002Fh",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Group 2 will receive a tranexamic acid dosage of 20mg\u002Fkg prior to operation start.",[18],"Drug: Tranexamic acid at a dose of 20 mg\u002Fkg",{"label":20,"type":10,"description":21,"interventionNames":22},"Group 3","Group 3 will receive a tranexamic acid dosage of 30mg\u002Fkg prior to operation start.",[23],"Drug: Tranexamic acid at a dose of 30 mg\u002Fkg",[25,31,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Tranexamic acid at a dose of 10 mg\u002Fkg followed by 1 mg\u002Fkg\u002Fh","Group 1: administration of tranexamic acid at a dose of 10 mg\u002Fkg followed by 1 mg\u002Fkg\u002Fh",[9],[9],{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Tranexamic acid at a dose of 20 mg\u002Fkg","Group 2: administration of tranexamic acid at a dose of 20 mg\u002Fkg",[15],[15],{"type":26,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Tranexamic acid at a dose of 30 mg\u002Fkg","Group 3: administration of tranexamic acid at a dose of 30 mg\u002Fkg",[20],[20],[42],{"name":43,"affiliation":5,"role":44},"Evangelia Samara","PRINCIPAL_INVESTIGATOR",[46],{"name":43,"role":47,"phone":48,"phoneExt":49,"email":50},"CONTACT","6972325749",null,"gelysamara@uoi.gr",[52],{"facility":53,"status":54,"city":55,"state":49,"zip":49,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"University Hospital of Ioannina","RECRUITING","Ioannina","Greece","GR",{"type":59,"coordinates":60},"Point",[61,62],20.85187,39.66341,{"lat":62,"lon":61},[65],{"name":43,"role":47,"phone":48,"phoneExt":49,"email":66},"gelysamara@yahoo.com",{"type":44,"investigatorFullName":43,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":49,"oldOrganization":49},"Assistant Professor of Anaesthesiology","100605575","comparative-study-of-tranexamic-acid-dosing-in-cardiac-surgery-100605575",false,"NCT07164300","Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery","Comparative Study of Tranexamic Acid Dosage Regimens in Patients Undergoing Cardiac Surgery Under Cardiopulmonary Bypass","Inclusion Criteria:\n\n* Patients undergoing elective cardiac surgery using cardiopulmonary bypass\n* Patients to have discontinued anticoagulant and antiplatelet therapy preoperatively according to guidelines.\n\nExclusion Criteria:\n\n* Age below 18 years\n* Patient refusal\n* Pregnancy\n* End-stage renal disease\n* History of epilepsy,\n* Cardiac surgery without the use of cardiopulmonary bypass (off-pump)\n* Emergency operations\n* Known allergy to the administered agents.","ALL","18 Years","99 Years",{"count":80,"type":81},150,"ESTIMATED","INTERVENTIONAL",[84],"NA","Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of tranexamic acid that should be administered. The purpose of this study is to compare different dosages of tranexamic acid in cardiac surgery using cardiopulmonary bypass regarding the duration of inhibition of fibrinolysis as measured by the ClotPro test.\n\nBlood samples will be taken from the arterial line placed in the patient at specified time points in order to perform viscoelastic tests (ClotPro, TPA test), to detect successful inhibition of fibrinolysis and to measure tranexamic acid levels in the patient's blood. In case the action of tranexamic acid stops early postoperatively an additional dose of the medication will be administered to the patient.",[87,88,89,90,91],"Blood Coagulation Disorder","Postoperative Blood Loss","Adverse Drug Event","Fibrinolysis; Hemorrhage","Tranexamic Acid Adverse Reaction","2025-09-05",{"date":94,"type":95},"2025-09-10","ACTUAL",{"date":97,"type":95},"2024-05-14",{"date":99,"type":81},"2027-12-15",{"name":5,"class":6},1]